Abstract
During the last 30 years, 5-fluorouracil (FUra)* has been the drug of choice for treatment of patients with adenocarcinoma of the colon. This agent is also active against breast carcinoma and has significant activity in carcinoma of the head and neck. In all cases, but especially in colon carcinoma, the response rate is low and the duration of response is relatively short, on the order of 6 to 9 months.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
D.S. Martin, R.L. Stolfi, R.C. Sawyer, and C.W. Young. The application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat. Rep., 69: 421–423 (1985).
D.S. Martin, R.L. Stolfi, and S. Spiegelman, Striking augmentation of the in vivo anticancer activity of 5-fluorouracil by combination with pyrimidine nucleosides: an RNA effect, Proc. Am. Assoc. Cancer Res. 19: 221 (1978).
R. Nayak, D.S. Martin, R.L. Stolfi, J. Furth, and S. Spiegelman. Pyrimidine nucleosides enhance the anticancer activity of 5-fluorouracil and augment its incorporation into nuclear RNA, Proc. Am. Assoc. Cancer Res. 19: 1963 (1978).
D.S. Martin, R.L. Stolfi, R.C. Sawyer, R. Nayak, S. Spiegelman, C.W. Young, and T. Woodcock. An overview of thymidine, Cancer 45: 1117–1128 (1980).
R.I. Glazer and K.D. Hartman. The effect of 5-fluorouracil on the synthesis and methylation of low molelcular weight nuclear RNA in L1210 cells, Mol. Pharmacol., 17: 245–249 (1979).
D.W. Kufe, P.P. Major, E.M. Egan, and E. Loh. 5-Fluoro-2’-Deoxyuridine incorporation into L1210 DNA. J. Biol. Chem., 256: 8885–8888 (1981).
P.V. Danenberg, C. Heidelberger, M. Mulkins, and A.R. Peterson. the incorporation of 5-fluoro-2’-deoxyuridine into dNA of mammalian tumor cells. Biochem. Biophys. Res. Commun. 102: 654–558 (1981).
J.D. Schuetz, H.J. Wallace, and R.B. Diasio. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity, Cancer Res. 44: 1358–1363 (1984).
D.V. Santi, C.S. McHenry, and H. Sommer. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13: 471–480 (1974).
P.V. Danenberg. The role of reduced folates in the enhanced binding of FdUMP to dTMP synthetase. In: The Current Status of 5-Fluorouracil Leucovorin Calcium Combination, Bruckner, H.W. and Rustum, Y.M. eds., p. 5–11, Park Row Publishers, New York (1984).
J.A. Houghton and P.J. Houghton. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xeno-grafts maintained in immune-deprived mice, Cancer, 45: 1159–1167 (1980).
J.A. Houghton, S.J. Maroda, J.O. Philips, and P.J. Houghton. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res., 41: 144–149 (1981).
J.A. Houghton, C. Schmidt and P.J. Houghton. The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur. J. Cancer Clin. Oncol., 18: 347–354 (1982).
J.A. Houghton and P.J. Houghton. Basis for the interaction of 5-Fluorouracil and leucovorin in colon adenocarcinoma. In: The Current Status of 5-Fluorouracil-Leucovorin Calcium Combination, Bruckner, H.W. and Rustum, Y.M., eds., p. 23–32, Park Row Publishers, New York (1984).
R.M. Evans, J.D. Laskin and M.T. Hakala. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Pes., 41: 3288–3295 (1981).
M-B. Yin, S.F. Zakrzewski and M.T. Hakala. Relationship cf cellular folate cofactor pools to activity of 5-fluorouracil. Mol. Pharmacol. 23: 190–197 (1983).
F. Trave, Y.M. Rustum, N. Petrelli, L. Herrera, A. Mittelman, C. Frank and P.J. Creaven, Plasmic tumor tissue pharmacology of high dose intravenous 5-formyltetrahydrofolate in combination with 5-fluorouracil in patients with advanced colorectal carcinoma, J. Clinical Oncology 6: 1184 (1988).
R.J. Moran, C.P. Spears and C. Heidelberger, Biochemical determinants of tumor sensitivity to the fluorouracil: Ultrasensitive method for the determination of 5-fluorodeoxyuridine monophosphate and thymidylate synthase, Proc. Natl. Acad. Sci. USA 76: 1456 (1969).
L. Danhauser and Y.M. Rustum, A method for continuous drug infusion in unrestarained rats: Its application in the evaluation of the toxicity of 5-fluorouracil/thymidine combination, J. Lab. Clin. Med. 92: 1047 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Rustum, Y.M., Liu, L., Zhang, Z. (1988). Role of Dosf, Schedule and Route of Administration of 5-Formyltetra-Hydrofolate: Preclinical and Clinical Investigations. In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5607-3_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-5609-7
Online ISBN: 978-1-4684-5607-3
eBook Packages: Springer Book Archive